Radiotherapy and TRAIL for cancer therapy

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 184-193

  Niemoeller, Olivier M ^a   Belka, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Cancer treatment; Death receptors; Radiotherapy; TRAIL

Indexed keywords

CETUXIMAB; LEXATUMUMAB; MAPATUMUMAB; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE ESCALATION; RADIATION INJURY; SHORT SURVEY; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA;

EID: 84876096990     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.003     Document Type: Review

References (79)

1. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nature Medicine 2004, 10:789-799.
2. Goh H.S., Yao J., Smith D.R. P53 point mutation and survival in colorectal-cancer patients. Cancer Research 1995, 55:5217-5221.
3. Falschlehner C., Emmerich C.H., Gerlach B., Walczak H. TRAIL signalling: decisions between life and death. International Journal of Biochemistry & Cell Biology 2007, 39:1462-1475.
4. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal 1998, 17:1675-1687.
5. Li H.L., Zhu H., Xu C.J., Yuan J.Y. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
6. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X.D. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
7. Wang K., Yin X.M., Chao D.T., Milliman C.L., Korsmeyer S.J. BID: A novel BH3 domain-only death agonist. Genes & Development 1996, 10:2859-2869.
8. Eskes R., Desagher S., Antonsson B., Martinou J.C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Molecular and Cellular Biology 2000, 20:929-935.
9. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
10. Pan G.H., Orourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
11. Pan G.H., Ni J., Wei Y.F., Yu G.L., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
12. Schneider P., Bodmer J.L., Thome M., Hofmann K., Holler N., Tschopp J. Characterization of two receptors for TRAIL. FEBS Letters 1997, 416:329-334.
13. DegliEsposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.P., DuBose R.F., Goodwin R.G., Smith C.A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. Journal of Experimental Medicine 1997, 186:1165-1170.
14. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology 1997, 7:1003-1006.
15. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Molecular and Cellular Biology 2006, 26:7046-7055.
16. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
17. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal 2002, 21:4520-4530.
18. Safa A.R., Day T.W., Wu C.H. Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for cancer therapy. Current Cancer Drug Targets 2008, 8:37-46.
19. Suliman A., Lam A., Datta R., Srivastava R.K. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001, 20:2122-2133.
20. Chen X.F., Kandasamy K., Srivastava R.K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Research 2003, 63:1059-1066.
21. Yoshida T., Maeda A., Tani N., Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Letters 2001, 507:381-385.
22. Steele L.P., Georgopoulos N.T., Southgate J., Selby P.J., Trejdosiewicz L.K. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death and Differentiation 2006, 13:1564-1576.
23. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Masters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation 1999, 104:155-162.
24. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C.L., Lynch D.H. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nature Medicine 1999, 5:157-163.
25. Marini P., Schmid A., Jendrossek V., Faltin H., Daniel P.T., Budach W., Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005, 5.
26. Pacey S., Plummer R.E., Attard G., Bale C., Calvert A.H., Blagden S., Fox N.L., Corey A., de Bono J.S. Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. Journal of Clinical Oncology 2005, 23:205S.
27. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., Hill M., Mays T., McCoy T., Fox N.L., Halpern W., Corey A., Cohen R.B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. Journal of Clinical Oncology 2007, 25:1390-1395.
28. Herbst R.S., Mendolson D.S., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., Ing J., Kurzrock R., Novotny W., Eckhardt G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Journal of Clinical Oncology 2006, 24:124S.
29. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews Drug Discovery 2008, 7:1001-1012.
30. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine 2007, 13:1070-1077.
31. Smalley S.R., Kimler B.F., Evans R.G. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma-cells. International Journal of Radiation Oncology Biology Physics 1991, 20:207-211.
32. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., Clarke-Pearson D.L., Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine 1999, 340:1144-1153.
33. ElSayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. Journal of Clinical Oncology 1996, 14:838-847.
34. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006, 354:567-578.
35. Yin X.M., Wang K., Gross A., Zhao Y.G., Zinkel S., Klocke B., Roth K.A., Korsmeyer S.J. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891.
36. Rudner J., Jendrossek V., Lauber K., Daniel P.T., Wesselborg S., Belka C. Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 2005, 24:130-140.
37. Norbury C.J., Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004, 23:2797-2808.
38. Belka C., Rudner J., Wesselborg S., Stepczynska A., Marini P., Lepple-Wienhues A., Faltin H., Bamberg M., Budach W., Schulze-Osthoff K. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 2000, 19:1181-1190.
39. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:1754-1759.
40. Belka C., Schmid B., Marini P., Durand E., Rudner J., Faltin H., Bamberg M., Schulze-Osthoff K., Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001, 20:2190-2196.
41. Shankar S., Singh T.R., Chen X.F., Thakkar H., Firnin J., Srivastava R.K. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. International Journal of Oncology 2004, 24:1133-1140.
42. Shankar S., Singh T.R., Srivastava R.K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004, 61:35-49.
43. Rezacova M., Vavrova J., Vokurkova D. Ionizing radiation sensitizes leukemic MOLT-4 cells to TRAIL-induced apoptosis. Acta Medica (Hradec Kralove) 2008, 51:101-105.
44. Di Pietro R., Secchiero P., Rana R., Gibellini D., Visani G., Bemis K., Zamai L., Miscia S., Zauli G. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001, 97:2596-2603.
45. Hamasu T., Inanami O., Asanuma T., Kuwabara M. Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists. Journal of Radiation Research 2005, 46:103-110.
46. Maduro J.H., de Vries E.G.E., Meersma G.J., Hougardy B.M.T., van der Zee A.G.J., De Jong S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. International Journal of Radiation Oncology Biology Physics 2008, 72:543-552.
47. Nagane M., Cavenee W.K., Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. Journal of Neurosurgery 2007, 106:407-416.
48. Weinmann M., Marini P., Jendrossek V., Betsch A., Goecke B., Budach W., Belka C. Influence of hypoxia on trail-induced apoptosis in tumor cells. International Journal of Radiation Oncology Biology Physics 2004, 58:386-396.
49. Aldridge D.R., Arends M.J., Radford I.R. Increasing the susceptibility of the rat 208f fibroblast cell-line to radiation-induced apoptosis does not alter its clonogenic survival dose - response. British Journal of Cancer 1995, 71:571-577.
50. Gong B.D., Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Research 2000, 60:5754-5760.
51. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics 2007, 6:1186-1197.
52. Takahashi M., Yasui H., Ogura A., Asanuma T., Kubota N., Tsujitan M., Kuwabara M., Inanami O. X irradiation combined with TNF alpha-related apoptosis-inducing ligand (TRAIL) reduces hypoxic regions of human gastric adenocarcinoma xenografts in SCID mice. Journal of Radiation Research 2008, 49:153-161.
53. Ichikawa K., Liu W.M., Zhao L.M., Wang Z., Liu D., Ohtsuka T., Zhang H.G., Mountz J.D., Koopman W.J., Kimberly R.P., Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Medicine 2001, 7:954-960.
54. Marini P., Denzinger S., Schiller D., Kauder S., Welz S., Humphreys R., Daniel P.T., Jendrossek V., Budach W., Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006, 25:5145-5154.
55. Marini P., Budach W., Niyazi M., Junginger D., Stickl S., Jendrossek V., Belka C. Combination of the pro-apoptotic trail-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. International Journal of Radiation Oncology Biology Physics 2009, 75:198-202.
56. J.B. Fiveash, G.Y. Gillespie, P.G. Oliver, T. Zhou, M.L. Belenky, D.J. Buchsbaum, Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5, in, 2008, pp. 507-516.
57. Kim M.R., Lee J.Y., Park M.T., Chun Y.J., Jang Y.J., Kang C.M., Kim H.S., Cho C.K., Lee Y.S., Jeong H.Y., Lee S.J. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. Febs Letters 2001, 505:179-184.
58. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., Carpenter M., LoBuglio A.F. Antitumor efficacy of TRA-8 Anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clinical Cancer Research 2003, 9:3731-3741.
59. Ramp U., Caliskan E., Mahotka C., Krieg A., Heikaus S., Gabbert H.E., Gerharz C.D. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. British Journal of Cancer 2003, 88:1800-1807.
60. Ivanov V.N., Zhou H.N., Hei T.K. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Research 2007, 67:5397-5407.
61. Wissink E.H.J., Verbrugge I., Vink S.R., Schader M.B., Schaefer U., Walczak H., Borst J., Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiotherapy and Oncology 2006, 80:214-222.
62. Verbrugge I., Maas C., Heijkoop M., Verheij M., Borst J. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death and Differentiation 2010, 17:551-561.
63. Kolesnick R., Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
64. Finnberg N., Gruber J.J., Fei P.W., Rudolph D., Bric A., Kim S.H., Burns T.F., Ajuha H., Page R., Wu G.S., Chen Y.H., McKenna W.G., Bernhard E., Lowe S., Mak T., El-Deiry W.S. DR5 knockout mice are compromised in radiation-induced apoptosis. Molecular and Cellular Biology 2005, 25:2000-2013.
65. Finnberg N., Klein-Szanto A.J.P., El-Deiry W.S. TRAU-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. Journal of Clinical Investigation 2008, 118:111-123.
66. Wang S.L., El-Deiry W.S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Research 2004, 64:6666-6672.
67. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., Schutz G., Greiner E.F., Kemp C.J., Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Journal of Clinical Investigation 2008, 118:100-110.
68. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., Lee J.H., Lee S.K., Lee S.N., Jung S.S., Han J.Y., Kim H., Lee J.Y., Yoo N.J. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Research 2001, 61:4942-4946.
69. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. Journal of Immunology 1998, 161:2833-2840.
70. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., Peter M.E., Yang X.L. c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo Journal 2002, 21:3704-3714.
71. Spencer S.L., Gaudet S., Albeck J.G., Burke J.M., Sorger P.K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009, 459. 428-U144.
72. Verbrugge I., de Vries E., Tait S.W.G., Wissink E.H.J., Walczak H., Verheij M., Borst J. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008, 27:574-584.
73. Wendt J., von Haefen C., Hemmati P., Belka C., Dorken B., Daniel P.T. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005, 24:4052-4064.
74. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., Smith C.A., Goodwin R.G., Kubin M.Z. Functional analysis of TRAIL receptors using monoclonal antibodies. Journal of Immunology 1999, 162:2597-2605.
75. Luciano F., Ricci J.E., Herrant M., Bertolotto C., Mari B., Cousin J.L., Auberger P. T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma. Leukemia 2002, 16:700-707.
76. Miyashita T., Reed J.C. Tumor-suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
77. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
78. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell 2001, 7:683-694.
79. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., Dimanche-Boitrel M.T. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003, 22:1807-1816.